Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
07/10/17Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors
– With up to 20 Months of Dosing, Fitusiran Safety and Tolerability Profile Remains Encouraging – – Once Monthly, Subcutaneous Fitusiran Achieves Median Annualized Bleeding Rate (ABR) of One for All Patients and Zero for Patients with Inhibitors in Exploratory Post-hoc Analysis – – New England Journal of Medicine Publishes Phase 1 Clinical Results with Fitusiran in Patients with Hemophilia A and B without Inhibitors – – Aln... 
Printer Friendly Version
07/07/17Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
– ATLAS to Evaluate Safety and Efficacy of Fitusiran Across Broad Spectrum of Patients Living with Hemophilia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the initiation of the ATLAS Phase 3 clinical program for fitusiran. The global, multicenter program is des... 
Printer Friendly Version
06/26/17Alnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
– In Randomized, Double-Blind, Placebo-Controlled Study, Givosiran Demonstrates Decreased Annualized Attack Rate and Hemin Usage – – Initial Results from Ongoing Open Label Extension (OLE) Study Show Consistent Reductions in Porphyria Attacks with Continued Givosiran Treatment – – Givosiran Administration Generally Well Tolerated with Treatment up to 12 Months – – Company Plans to Initiate Phase 3 Clinical Program in Late 2... 
Printer Friendly Version
06/26/17Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress
– New Data from an Ongoing Phase 2 Open-label Extension Study with Fitusiran in Patients with Hemophilia A and B, With or Without Inhibitors– CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 26, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2 open-label extension (OLE) study wi... 
Printer Friendly Version
06/19/17Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 19, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.D., has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2017-2018 term. “BIO has long supported the innovative, transformative work of the biotech community, and it is an honor to serve a... 
Printer Friendly Version
06/12/17Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office
– McSwiggen '354 Covers Single-Stranded RNA Therapeutics Targeting Transthyretin – – Manoharan '612 Covers RNA Therapeutics of Any Length with GalNAc Conjugates of Any Valency – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two pat... 
Printer Friendly Version
06/07/17Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18 Organizations
- Alnylam Supports Local Organizations in the Greater Boston Area, Maidenhead, UK and Zug, Switzerland - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its third annual company-wide “Helping Hands” Community Service Day benefiting 18 organizations in the Greater Boston area, Maidenhead, UK and Zug, Switzerland. Employees are encouraged to ... 
Printer Friendly Version
05/31/17FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria
– Additional Phase 1 Results to be Presented at the International Congress on Porphyrins and Porphyrias (ICPP), June 25 - 28, 2017 – – Company Plans to Initiate Phase 3 Clinical Program in Late 2017 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Admin... 
Printer Friendly Version
05/30/17Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 30, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 9:00 am ET in New York City. A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.alnylam.com. A replay ... 
Printer Friendly Version
05/24/17Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to b... 
Printer Friendly Version
05/23/17Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. All of the shares in the o... 
Printer Friendly Version
05/12/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Manmeet S. Soni, the Company's newly appointed Chief Financial Officer. The compensation committee of Alnylam's board of directors approved the grant, effective as of May 8, 2017, to Mr. Soni of non-qualified stock options to purchase an aggregate of 150,000 shar... 
Printer Friendly Version
05/10/17Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 at 8:40 am PT (11:40 am ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada, and at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:00 a... 
Printer Friendly Version
05/09/17Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders
– Company Appoints Chief Financial Officer and Other Key Roles Ahead of Anticipated Transition to Commercialization – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S. Soni, Chief Financial Officer; Theresa Heggie, Senior Vice President, Head of ... 
Printer Friendly Version
05/05/17Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
– Advanced Industry-Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late-Stage Development – – Maintained Strong Balance Sheet with $962 Million in Cash and Plans to End 2017 with Greater than $700 Million in Cash – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial re... 
Printer Friendly Version
04/27/17Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the U.S. financial markets open. Management will provide an update on the company and discuss first quarter 2017 results as well as expectations for the future via confere... 
Printer Friendly Version
04/26/17Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
– Patisiran Achieves Mean 7.0 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7), Comparing Favorably with Expected Mean 26-30 Point Increase Estimated from Historical Data – – In New Post-Hoc Analysis, Evidence for Potential Halting or Improvement of Neuropathy Progression Seen Across Broad Range of Baseline Neuropathy Severity – – In Addition, Company Reports First-Ever Histological Evidence for Decrease in Dermal TT... 
Printer Friendly Version
04/26/17The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced that T... 
Printer Friendly Version
03/28/17Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the c... 
Printer Friendly Version
03/01/17Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The purpose of the PRIME initiative is to b... 
Printer Friendly Version
02/28/17Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis
– Alnylam Act™ sponsors free third-party genetic counseling and testing services for people at risk for hereditary ATTR amyloidosis (hATTR amyloidosis) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today marked the 10th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers impacted by specific rare ... 
Printer Friendly Version
02/27/17Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017 at 2:40 pm ET at the Boston Marriott Copley Place Hotel in Boston, Massachusetts and at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 9:30 am ... 
Printer Friendly Version
02/10/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors, approved a grant, effective as of February 6, 2017, to a vice president level employee of the Company, of a non-qualified stock option to purchase 50,000 shares of Alnylam's common s... 
Printer Friendly Version
02/07/17Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 pm ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor... 
Printer Friendly Version
02/02/17Alnylam Presents New Data on Fitusiran at EAHAD
– New Phase 1 Results Demonstrate Effective Bleed Management with Replacement Factor and Bypassing Agents During Fitusiran Administration – – Stability Study Results Support a Greater than Two Year Product Shelf-Life at Room Temperature Storage Conditions – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from... 
Printer Friendly Version
02/01/17Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S. financial markets close. Management will provide an update on the company and discuss fourth quarter and year-end 2016 results as well as expectations... 
Printer Friendly Version
01/03/17Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version
01/03/17Alnylam Announces Management Change and Key Promotion
– Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David-Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons. His resignation will be effective... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.